The authors report case of a two and half years old female child presented with fever for one month with hepatosplenomegaly. Though the child had been symptomatic for a prolonged period, she did not appear very unwell at presentation. However, after admission there was sudden rapid deterioration of her clinical status. Investigations revealed hemophagocytosis with brucella infection.

Goldenhar syndrome is a variant of hemifacial microsomia. It is not usually associated with mental retardation; even if present it is mild to moderate. In this case both profound mental retardation and bilateral facial microsomia are present. Early identification and intervention can improve the intellectual functioning, otherwise favorable prognosis. INTRODUCTION: In 1952 Maurice Goldenhar described a variant of hemifacial microsomia called Goldenhar syndrome. It results from an aberrant development of the 1 st and 2 nd branchial arches. It has an incidence of approximately 1 in 5600, more common among males with a ratio of 2:1 and also common among whites. [1] Goldenhar syndrome is a form of occulo-auriculo-vertebral spectrum (OAVS), as a minimal sign microtia must be present. [2] It presents bilaterally in 10-33% of cases. [3] About 10% of children may have mental retardation, usually mild to moderate. [4] Here we report a case of Goldenhar syndrome with profound mental retardation which is very unusual.

Objectives: To study the safety profile of live JE vaccine. To analyse the possible risk factors for development of adverse events.Methods: 1500 children aged 1 year to 15 years, vaccinated with live JE vaccine during a mass vaccination campaign, were followed up for a period of 6 months from the time of vaccination. Outcome measures were major and minor adverse events during the first two weeks and any neurological events thereafter. Results:No serious adverse reactions were noted in the 1 st two weeks following vaccination. 22.3% reported minor events like fever, headache, upper respiratory symptoms, vomiting, rashes and local reactions. Those with a personal or family history of atopy showed an increased risk of adverse events. No significant correlation between age, sex, or nutritional status and risk for development of adverse events were noted. None of the vaccine recipients experienced any major neurological events within next 6 M. Conclusion:Live attenuated JE vaccine is safe in children below 15 years. Those with a history of atopy have a higher risk of developing minor adverse events following the vaccine.